Do anticoagulants affect outcomes of hip fracture surgery?  
A cross-sectional analysis

Caroline Hoerlyck1 · Terence Ong2,3 · Merete Gregersen4 · Else Marie Damsgaard4 · Lars Borris5 · Jac Kie Chia2 · Ying Yi Wendy Yap2 · Namal Weerasuriya2 · Opinder Sahota2

Received: 24 January 2019 / Published online: 21 September 2019
© The Author(s) 2019

Abstract

Introduction The management of patients with a hip fracture is affected by the use of oral anticoagulants. A cross-sectional analysis was undertaken to investigate health outcome differences in those anticoagulated compared to those not anticoagulated.

Methods Patients aged 50 years and over presenting to a large university hospital with hip fractures were identified from the service registry. Patient characteristics and health outcomes between those not anticoagulated were compared with those anticoagulated (warfarin and direct oral anticoagulants, DOAC).

Results 200/2307 (9%) patients were anticoagulated. 84% were on warfarin, and the rest a DOAC. Compared to those anticoagulated, there was a higher prevalence of dementia (25% vs. 18%, \( p = 0.02 \)) and a lower prevalence of cardiovascular disease (54% vs. 78%, \( p < 0.01 \)), atrial fibrillation (10% vs. 82%, \( p < 0.01 \)), and polypharmacy (55% vs. 76%, \( p < 0.01 \)). Renal function was lower in the anticoagulated group. Time to operation for those not anticoagulated and anticoagulated was a median (IQR) of 25 (15) and 27 (18) hours. There was no difference in blood transfusion and hospital mortality. Postoperative complications were similar except a higher rate of renal failure (14% vs. 19%, \( p = 0.04 \)) and heart failure (1% vs. 5%, \( p < 0.01 \)), and a longer length of stay [median (IQR): 14 (10) vs. 16 (12) days] in the anticoagulated group. This was no longer significant after adjustment of confounders.

Conclusion There was no statistically significant difference in health outcomes between those anticoagulated and those not after adjusting for patient characteristics. It was feasible to avoid significant delay in hip fracture surgery in those anticoagulated.

Keywords Anticoagulants · Warfarin · DOAC · Hip fractures · Trauma

Introduction

A hip fracture is a devastating injury that carries with its poor health outcomes. The overall number of hip fractures is expected to go up with the expected increase in number of older people [1]. Consequently, its negative socioeconomic impact worldwide will also increase significantly [2]. Surgery conducted within 48 h has been shown to improve these outcomes [3–12]. An operative wait beyond this time increases the risk of developing post-fracture complications [11, 12] and is associated with a 30-day and one-year mortality of 40% and 30%, respectively [9]. A recent study has reported that even a waiting time of more than 24 h was associated with worse outcomes, suggesting that this may be the threshold where adverse outcomes starts to increase [13]. Hence, minimising surgical delay appears to be an important factor in improving patient’s prognosis from their hip fracture.

Anticoagulated patients presenting with a hip fracture have been associated with delays in surgical fixation [14–18]. The potential need for reversal and fear of bleeding has been postulated as reasons for this delay. Clinical data have reported that in recent years there has been a steady increase in the number
of people prescribed anticoagulation medication [19]. Therefore, it is anticipated that there will be more people prescribed oral anticoagulation presenting with hip fractures. There remains uncertainty of how best to manage these patients and their varied anticoagulation, of either a vitamin K antagonist, e.g. warfarin, or one of the new direct oral anticoagulants (DOACs). The aim of this study was to compare patient characteristics and outcomes of those on oral anticoagulation and those not, presenting to hospital with a hip fracture.

Methods

A cross-sectional analysis was undertaken from the hip fracture registry of a large university hospital, Queens Medical Centre, Nottingham, UK. Characteristics and outcomes between patients presenting with hip fractures on oral anticoagulants (warfarin and DOAC) and those not anticoagulated were compared. The hospital’s hip fracture registry gathers information on all patients admitted to hospital with a hip fracture based on documentation made in clinical notes by the respective patients’ team. The data are sourced by audit data clerical staff from relevant clinical notes and entered electronically onto a hospital-secured electronic database. Patients aged 50 years and over admitted from 1 August 2013 to 29 July 2016 were identified from this registry. Patients were excluded if the fracture was attributed to a high impact trauma, secondary to cancer or if the fracture was not anticoagulated, except that the anticoagulated group, but after controlling for confounders no other group was included in the regression model. To examine possible confounding and effect modification, we tested interactions between number of comorbidities and length of stay, polypharmacy and length of stay, atrial fibrillation and heart failure, number of comorbidities and renal failure and, finally, gender and renal failure. Missing values were dropped from analysis as the numbers were small representing less than 2.5% of the overall dataset. Significance threshold for all variables and interaction terms was set at a probability less than 0.05. All analyses were conducted using STATA version 15.

Results

Data were analysed for 2307 patients. 200 patients (8.7%) were receiving an anticoagulant (warfarin or DOAC) at the time of admission. The majority were prescribed warfarin (167/200 patients, 83.5%) and atrial fibrillation was the most common indication (81.5%). Mean (SD) INR (International Normalised Ratio) of patients on warfarin preoperatively was 1.38 (0.2). Among patients on a DOAC, 22/33 patients (66.7%) were prescribed rivaroxaban and 11/33 patients (33.3%) prescribed apixaban. Patient characteristics were comparable between those anticoagulated and those not anticoagulated, except that the anticoagulated group had more men, a higher comorbid burden, less likely to be living with dementia, have a higher prevalence of cardiovascular disease, atrial fibrillation, polypharmacy, better cognition, and worse preoperative renal function (Table 1 in “Appendix”).

Time to operation from admission to hospital was a median of 27 h in the anticoagulated group and 25 h in the non-anticoagulated group (p < 0.01). There was no difference in need for blood transfusion (Table 2 in “Appendix”). More from the anticoagulated group suffered postoperatively from heart failure (5.15% vs. 1.25%; p = 0.01) and renal failure (19% vs. 13.7%; p = 0.04). Otherwise, there were no differences in postoperative chest infection, urinary tract infection, haematoma and pressure ulcers (Table 2 in “Appendix”). Hospital mortality was similar in both groups (6.5% vs. 6.79%; p = 0.88). In the anticoagulated group, the median length of stay was 16 days and 14 days in the non-anticoagulated group (p < 0.01).

Length of stay was significantly longer, and the incidence of heart failure and renal failure was significantly higher in the anticoagulated group, but after controlling for confounders no longer became significant (Table 3 in “Appendix”).

Discussion

Hip fractures are a rapidly growing international public health problem. Many of the patients are older with multiple comorbidities of which some will require...
anticoagulation which will affect their hip fracture management. In this large cross-sectional analysis, the average patient with a hip fracture was in the ninth decade of life with at least two existing comorbid illnesses. There were differences in patient characteristics between those anticoagulated and those not anticoagulated. There were more men, a higher prevalence of cardiovascular disease, atrial fibrillation, worse renal function and better cognition in the anticoagulated group. Comparing these two groups’ outcomes, they were similar in relation to mortality, need for blood transfusion and postoperative complication, except the number of heart and renal failure. Length of stay appeared longer in the anticoagulated group. However, after adjusting for confounders, these postoperative complications and length of stay were no longer statistically different between the two groups.

Using a service registry to perform this cross-sectional analysis has limitations. Data reported were dependent on routine data collected as part of this registry. Information such as the prevalence of osteoporosis, comorbid burden (e.g. using the Charlson Comorbidity Index), haemoglobin levels, and complications such as delirium and thromboembolic event was not reported. In addition, the robustness of the data in this group of patients also very much depends on what is recorded by the patients’ clinical team. Besides that, the quality of the data entry may also affect the data accuracy. However, as the registry has been operational for almost 15 years, the local audit department has a wealth of experience to ensure data accuracy and missing data are minimised. This is seen in this analysis as the amount of missing data was less than 2.5% of a very large dataset capturing 3 years of patient level data. This study analysis was also limited by data that were only collected in this registry. Hence, there are likely confounding factors that we did not account for which might have affected the outcomes, for example sarcopenia and nutritional state. It was not possible to perform a subgroup analysis of patients on DOAC due to the low numbers.

To date, studies investigating the postoperative outcomes of patients admitted with hip fractures on anticoagulation have been mixed. One study found that neither time to surgery nor length of stay was significantly different when comparing those anticoagulated with warfarin and those not anticoagulated. Furthermore, they found no significant differences in thromboembolic event rates, bleeding complication, mortality, or 30-day readmission after surgery compared to those not taking warfarin on admission [20]. Another study reported that patient admitted on warfarin was associated with increased length of stay and lower survival at 12-months. Crucially, those anticoagulated had longer wait to surgery which can reach up to 46 h [16, 17]. The mixed picture could potentially be explained by the variability in how local practices differ in perioperative management of anticoagulation. To our knowledge, there are no prevailing national or international guidelines on how these patients should be managed and local consensus dictates clinical practice.

The biggest challenge in the management of patients with hip fracture on anticoagulation is how to safely deliver surgery. The advantage of warfarin is its ease in reversing its anticoagulation effect, it is possible to monitor its therapeutic effect, and being widely used mean clinicians have much more experience in addressing its anticoagulation effect in the peri-operative phase. DOACs lack that in clinical practice. Coagulation assays which have long been used to monitor drug anticoagulation effects are unreliable in DOACs. Anti-factor Xa levels can be checked to measure the effect of rivaroxaban, apixaban or edoxaban. Drug assay concentration is another option. However, these tests have their own limitation with reliability and standardised calibration. Hence, their use is not widespread and its place in routine clinical practice remains uncertain. Only one of the DOAC, dabigatran, has a specific reversal agent, idarucizumab. Its cost has restricted its widespread use. A recent study using audit data from a single hospital reported that hip fracture surgery for patients taking DOAC had a median time to theatre of 19 h [22]. Compared to a matched cohort, there was no difference in perioperative haemoglobin concentration, requirement for transfusion and reoperation suggesting that early surgery is possible even for patients on DOACs [22]. Our own study reported a median time to theatre of 27 h, which is within the required 36 h to achieve UK Best Practice Tariff for hip fracture management, a payment tariff for hospitals set nationally. Further research is clearly still required to better understand DOAC in the surgical setting [21].

### Conclusion

In this large cross-sectional analysis of a single university hospital’s trauma unit of people presenting with an acute hip fracture, we found that there was no significant difference in outcomes between those presenting on anticoagulated and those not. Prompt time to theatre can be safely delivered in those presenting on anticoagulation.

### Acknowledgements

We would like to thank Jess Nightingale, audit lead for the Department of Trauma and Orthopaedics, Nottingham University Hospitals NHS Trust, and the audit department who assisted with sourcing the data. C.H. was on a clinical attachment and had an honorary contract with the Trust. T.O. is a recipient of a research training fellowship from the Dunhill Medical Trust (Grant number RTF49/0114). No funds were obtained for this study.

### Funding

There is no funding source.
Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest related to this work.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Appendix

See Tables 1, 2, 3.

Table 1 Characteristics of patients not on anticoagulation and patients on anticoagulation

| Measure                                      | Not on anticoagulation | On anticoagulation (n = 200; 167 on warfarin, 33 on DOAC) | p value |
|----------------------------------------------|------------------------|-----------------------------------------------------------|---------|
| Age, Mean (SD), years                       | 82.1 (9.9)             | 83.1 (7.6)                                                | 0.08    |
| 95% CI                                       | 81.7–82.5              | 82.0–84.2                                                 |         |
| Gender                                       |                        |                                                           |         |
| Male, n (%)                                  | 594 (28)               | 75 (38)                                                   | 0.01    |
| Female, n (%)                                | 1513 (72)              | 125 (63)                                                  |         |
| Comorbidities                                |                        |                                                           |         |
| Malignancy, n (%)                            | 294 (14)               | 25 (13)                                                   | 0.57    |
| Dementia, n (%)                              | 531 (25)               | 35 (18)                                                   | 0.02    |
| CVD, n (%)                                   | 1138 (54)              | 155 (78)                                                  | <0.01   |
| Diabetes Mellitus, n (%)                     | 331 (16)               | 42 (21)                                                   | 0.05    |
| COPD, n (%)                                  | 275 (13)               | 32 (16)                                                   | 0.24    |
| Renal disease, n (%)                         | 343 (16)               | 37 (19)                                                   | 0.42    |
| Hypertension, n (%)                          | 931 (44)               | 87 (44)                                                   | 0.85    |
| Atrial fibrillation, n (%)                   | 207 (10)               | 163 (82)                                                  | <0.01   |
| Number of comorbidities                      |                        |                                                           |         |
| Median (IQR)                                 | 2 (2)                  | 3 (2)                                                     | <0.01   |
| Polypharmacy* n (%)                          | 1150 (55)              | 152 (76)                                                  | <0.01   |
| Medication use                               |                        |                                                           |         |
| Aspirin, n (%)                               | 454 (22)               | 3 (2)                                                     | <0.01   |
| Clopidogrel, n (%)                           | 167 (8)                | 2 (1)                                                     | <0.01   |
| ASA grade                                    |                        |                                                           | <0.01   |
| 1, n (%)                                     | 51 (2)                 | 1 (0.50)                                                  |         |
| 2, n (%)                                     | 442 (21)               | 18 (9)                                                    |         |
| 3, n (%)                                     | 921 (44)               | 99 (50)                                                   |         |
| 4, n (%)                                     | 280 (13)               | 42 (21)                                                   |         |
| 5, n (%)                                     | 7 (0.33)               | 2 (1)                                                     |         |
| Not stated, n (%)                            | 406 (19)               | 38 (19)                                                   |         |
| AMT score                                    |                        |                                                           | <0.01   |
| 0–6, n (%)                                   | 693 (33)               | 40 (20)                                                   |         |
| 7–10, n (%)                                  | 1366 (65)              | 154 (77)                                                  |         |
| Not stated, n (%)                            | 48 (2)                 | 6 (3)                                                     |         |
| Preoperative haemoglobin Mean (SD), g/dL     | 12.6 (5.5)             | 12.4 (2.0)                                                | 0.59    |
| Preoperative eGFR Mean (SD), ml/min/1.73 m²  | 68.42 (20.83)          | 63.33 (20.80)                                             | <0.01   |

SD standard deviation, CVD cardiovascular disease, COPD chronic obstructive pulmonary disease, IQR interquartile range, ASA American Society of Anaesthesiologists, AMT abbreviated mental test, eGFR estimated glomerular filtration rate

*Four or more medications
Table 2  Outcomes of patients not on anticoagulation and patients on anticoagulation

| Measure                        | Not on anticoagulation (n = 2107) | On anticoagulation (n = 200) | p value |
|--------------------------------|----------------------------------|-----------------------------|---------|
| Time to operation              |                                  |                             |         |
| Median (IQR), h                | 25 (15)                          | 27 (17.5)                   | <0.01   |
| Blood transfusion              |                                  |                             |         |
| Preoperatively, n (%)          | 71 (3)                           | 7 (4)                       | 0.92    |
| Intra-operatively, n (%)       | 13 (1)                           | 3 (2)                       | 0.15    |
| Postoperatively, n (%)         | 500 (24)                         | 56 (28)                     | 0.18    |
| Length of stay                 |                                  |                             |         |
| Median (IQR), days             | 14 (10)                          | 16 (12)                     | <0.01   |
| Health outcomes                |                                  |                             |         |
| Heart failure, n (%)*          | 26 (1)                           | 10 (5)                      | <0.01   |
| Renal failure, n (%)           | 288 (14)                         | 38 (19)                     | 0.04    |
| Chest infection, n (%)         | 276 (13)                         | 24 (12)                     | 0.66    |
| UTI, n (%)                     | 208 (10)                         | 20 (10)                     | 0.95    |
| Haematoma, n (%)               | 24 (1)                           | 5 (3)                       | 0.10    |
| Pressure ulcer, n (%)          | 39 (2)                           | 2 (1)                       | 0.38    |
| Serious wound or deep infection, n (%) | 20 (1) | 2 (1) | 1.0 |
| Stroke, n (%)                  | 10 (0.5)                         | 0 (0)                       | 1.0     |
| Myocardial infarction, n (%)   | 40 (2)                           | 2 (1)                       | 0.58    |
| Hospital mortality, n (%)      | 143 (7)                          | 13 (6.5)                    | 0.88    |

IQR interquartile range, UTI urinary tract infection
*Missing data on 33 in the not anticoagulated group and 6 in the anticoagulated group

Table 3  Linear regression analysis of length of stay, heart failure and renal failure

| Statistical analysis                        | Coefficient | 95% confidence interval | p value |
|---------------------------------------------|-------------|-------------------------|---------|
| Length of stay                              | Crude estimate 1.14 | 1.05 to 1.24 | <0.01  |
|                                              | Adjusted estimate* 1.04 | 0.94 to 1.14 | 0.49   |
|                                              | Test for interaction |             |         |
|                                              | Number of comorbidities −0.06 | −0.12 to 0.01 | 0.10 |
|                                              | Polyparmacy −0.15 | −0.34 to 0.04 | 0.12 |
| Heart failure                               | Crude estimate 4.28 | 2.03 to 9.02 | <0.01  |
|                                              | Adjusted estimate* 1.03 | 0.43 to 2.50 | 0.95   |
|                                              | Test for interaction |             |         |
|                                              | Atrial fibrillation 0.31 | 0.03 to 2.92 | 0.31   |
| Renal failure                               | Crude estimate 1.48 | 1.02 to 2.16 | 0.04   |
|                                              | Adjusted estimate* 1.09 | 0.69 to 1.73 | 0.70   |
|                                              | Test for interaction |             |         |
|                                              | Number of comorbidities 1.08 | 0.78 to 1.48 | 0.65   |
|                                              | Gender 1.08 | 0.50 to 2.31 | 0.85   |

*Adjusted for gender, dementia, atrial fibrillation, cardiovascular disease, number of comorbidities and polypharmacy
References

1. Wade SW, Strader C, Fitzpatrick LA, Anthony MS (2012) Sex- and age-specific incidence of non-traumatic fractures in selected industrialized countries. Arch Osteoporos 7:219–227
2. Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413
3. Hip fracture: management (2011) Clinical guideline. https://www.nice.org.uk/guidance/cg124. Accessed 21 Jan 2018
4. Leung F, Lau T, Kwan K, Chow S, Kung A (2010) Does timing of surgery matter in fragility hip fractures? Osteoporos Int 21(Suppl 4):S529–S534
5. Rosso F, Dettoni F, Bonasia DE et al (2016) Prognostic factors for mortality after hip fracture: operation within 48 hours is mandatory. Injury 47(Suppl 4):S91–S97
6. Al-Ani AN, Samuelsson B, Tidermark J et al (2008) Early operation on patients with a hip fracture improved the ability to return to independent living. A prospective study of 850 patients. J Bone Jt Surg Am 90(7):1436–1442
7. Ryan DJ, Yoshihara H, Yoneoka D, Egol KA, Zuckerman JD (2015) Delay in hip fracture surgery: an analysis of patient-specific and hospital-specific risk factors. J Orthop Trauma 29(8):343–348
8. Zuckerman JD, Skovron ML, Koval KJ, Aharonyoff G, Frankel VH (1995) Postoperative complications and mortality associated with operative delay in older patients who have a fracture of the hip. J Bone Jt Surg Am 77(10):1551–1556
9. Shiga T, Wajima Z, Ohe Y (2008) Is operative delay associated with increased mortality of hip fracture patients? Systematic review, meta-analysis, and meta-regression. Can J Anaesth 55(3):146–154
10. McGuire KJ, Bernstein J, Polsky D, Silber JH (2004) The 2004 Marshall Urist award: delays until surgery after hip fracture increases mortality. Clin Orthop Relat Res 428:294–301
11. Lefaivre KA, Macadam SA, Davidson DJ, Gandhi R, Chan H, Broekhuysen HM (2009) Length of stay, mortality, morbidity and delay to surgery in hip fractures. J Bone Jt Surg Br 91(7):922–927
12. Simunovic N, Devereaux PJ, Sprague S et al (2010) Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ 182(15):1609–1616
13. PinCUS D, Ravi B, Wasserstein D et al (2017) Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA 318(20):1994–2003
14. Fantini MP, Fabbri G, Laus M et al (2011) Determinants of surgical delay for hip fracture. Surgeon 9(3):130–134
15. Eardley WG, Macleod KE, Freeman H, Tate A (2014) “Tiers of delay”: warfarin, hip fractures, and target-driven care. Geriatr Orthop Surg Rehabil 5(3):103–108
16. Tran T, Deluc A, de Wit C, Petrich W, Le Gal G, Carrier M (2015) The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture. Thromb Res 136(5):962–965
17. Lawrence JE, Fountain D, Cundall-Curry D, Carrothers A (2017) Do patients taking warfarin experience delays to theatre, longer hospital stay, and poorer survival after hip fracture? Clin Orthop Relat Res 475(1):273–279
18. Ranhoff AH, Martinsen MI, Holvik K, Solheim LF (2011) Use of warfarin is associated with delay in surgery for hip fracture in older patients. Hosp Pract 39(1):37–40
19. Loo SY, Dell’Aniello S, Huiart L, Renoux C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 83(9):2096–2106
20. Gleason LJ, Mendelson DA, Kates SL, Friedman SM (2014) Anticoagulation management in individuals with hip fracture. J Am Geriatr Soc 62(1):159–164
21. Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507
22. Mullins B, Akehurst H, Slattery D, Chesser T (2018) Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. BMJ Open 8:e020625

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.